
Ting Luo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7022905/publications.pdf Version: 2024-02-01



TINCLUO

#	Article	lF	CITATIONS
1	Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial. Gland Surgery, 2022, 11, 216-225.	1.1	7
2	Abstract P2-13-32: Pyrotinib in combination with letrozole for estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer: A multicenter, single-arm, phase II trial. Cancer Research, 2022, 82, P2-13-32-P2-13-32.	0.9	0
3	Targeting extracellular matrix stiffness and mechanotransducers to improve cancer therapy. Journal of Hematology and Oncology, 2022, 15, 34.	17.0	117
4	Association between age at initial diagnosis and post-metastasis mortality among women with recurrent metastatic breast cancer in China. BMC Cancer, 2022, 22, 385.	2.6	10
5	Clinical characteristics and survival outcome of patients with estrogen receptor low positive breast cancer. Breast, 2022, 63, 24-28.	2.2	13
6	Dataâ€driven treatment pathways mining for early breast cancer using cSPADE algorithm and system clustering. International Journal of Health Planning and Management, 2022, 37, 2569-2584.	1.7	2
7	Public health insurance and cancerâ€specific mortality risk among patients with breast cancer: A prospective cohort study in China. International Journal of Cancer, 2021, 148, 28-37.	5.1	24
8	Cost-effectiveness of different surgical treatment approaches for early breast cancer: a retrospective matched cohort study from China. BMC Cancer, 2021, 21, 107.	2.6	6
9	The Effect of Postmastectomy Radiotherapy on Breast Cancer Patients After Neoadjuvant Chemotherapy by Molecular Subtype. Annals of Surgical Oncology, 2021, 28, 5084-5095.	1.5	4
10	ASO Author Reflections: Postmastectomy Radiotherapy for Breast Cancer Patients After Neoadjuvant Chemotherapy, by Molecular Subtype. Annals of Surgical Oncology, 2021, 28, 5096-5097.	1.5	0
11	SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion. Experimental Hematology and Oncology, 2021, 10, 17.	5.0	16
12	Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 351-360.	10.7	188
13	Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study. Frontiers in Oncology, 2021, 11, 664429.	2.8	16
14	Optimum adjuvant trastuzumab duration for human epidermal growth factor receptor-2 positive breast cancer: a network meta-analysis of randomized trials. Translational Cancer Research, 2021, 10, 1628-1643.	1.0	0
15	Treatment and prognosis of advanced triple-negative breast cancer patients with HER2-low expression: A 15-year retrospective study Journal of Clinical Oncology, 2021, 39, e13046-e13046.	1.6	0
16	Postmastectomy radiation therapy and survival outcome in older patients with T1-2N1 breast cancer. Breast, 2021, 59, 308-313.	2.2	4
17	The effect of postmastectomy radiation therapy on high-risk patients with T1-2N0 breast cancer. Breast, 2021, 60, 1-5.	2.2	4
18	A Retrospective Analysis of the Effect of Irinotecan-Based Regimens in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes. Frontiers in Oncology, 2021, 11, 654974.	2.8	3

Ting Luo

#	Article	IF	CITATIONS
19	Lipid Changes During Endocrine Therapy in Breast Cancer Patients: The Results of a 5-Year Real-World Retrospective Analysis. Frontiers in Oncology, 2021, 11, 670897.	2.8	4
20	Neoadjuvant Chemotherapy Combined with Transarterial Embolization to Treat an Inflammatory Breast Cancer with a Heavy Tumor Burden, Ulceration, and Exudation. Journal of Vascular and Interventional Radiology, 2021, , .	0.5	0
21	Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study. Frontiers in Oncology, 2020, 10, 271.	2.8	10
22	Realâ€world data of lapatinib and treatment after lapatinib in patients with previously treated HER2â€positive metastatic breast cancer: A multicenter, retrospective study. Cancer Medicine, 2020, 9, 2981-2988.	2.8	4
23	Multidimensional Machine Learning Personalized Prognostic Model in an Early Invasive Breast Cancer Population-Based Cohort in China: Algorithm Validation Study. JMIR Medical Informatics, 2020, 8, e19069.	2.6	8
24	Optimum duration of adjuvant trastuzumab in treatment of human epidermal growth factor receptor-2 positive early breast cancer: protocol for a network meta-analysis of randomised controlled trials. BMJ Open, 2020, 10, e035802.	1.9	1
25	Correction: Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer. Oncotarget, 2020, 11, 3484-3485.	1.8	1
26	Targeting mTOR for cancer therapy. Journal of Hematology and Oncology, 2019, 12, 71.	17.0	542
27	Advantages of using reduced-volume intensity modulated radiation therapy for the treatment of nasopharyngeal carcinoma: a retrospective paired study. BMC Cancer, 2019, 19, 554.	2.6	11
28	The regulatory protein GADD34 inhibits TRAIL-induced apoptosis via TRAF6/ERK-dependent stabilization of myeloid cell leukemia 1 in liver cancer cells. Journal of Biological Chemistry, 2019, 294, 5945-5955.	3.4	21
29	The natural agent rhein induces βâ€catenin degradation and tumour growth arrest. Journal of Cellular and Molecular Medicine, 2018, 22, 589-599.	3.6	13
30	Gamma synuclein is a novel Twist1 target that promotes TGF-β-induced cancer cell migration and invasion. Cell Death and Disease, 2018, 9, 625.	6.3	32
31	Improved anti-tumor efficacy via combination of oxaliplatin and fibrin glue in colorectal cancer. Oncotarget, 2018, 9, 2515-2526.	1.8	9
32	Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial. Chinese Journal of Cancer, 2017, 36, 27.	4.9	11
33	AMPK-mediated up-regulation of mTORC2 and MCL-1 compromises the anti-cancer effects of aspirin. Oncotarget, 2016, 7, 16349-16361.	1.8	36
34	mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. Cell Research, 2016, 26, 46-65.	12.0	103
35	Application status of tamoxifen in endocrine therapy for early breast cancer. Experimental and Therapeutic Medicine, 2015, 9, 2207-2212.	1.8	5
36	Reactive oxygen species-mediated activation of the Src-epidermal growth factor receptor-Akt signaling cascade prevents bortezomib-induced apoptosis in hepatocellular carcinoma cells. Molecular Medicine Reports, 2015, 11, 712-718.	2.4	23

Ting Luo

#	Article	IF	CITATIONS
37	Correlation between Activation of PI3K/AKT/mTOR Pathway and Prognosis of Breast Cancer in Chinese Women. PLoS ONE, 2015, 10, e0120511.	2.5	37
38	GSK3 Protein Positively Regulates Type I Insulin-like Growth Factor Receptor through Forkhead Transcription Factors FOXO1/3/4. Journal of Biological Chemistry, 2014, 289, 24759-24770.	3.4	38
39	Vascular Endothelial Growth Factor (VEGF) Gene Polymorphisms and Breast Cancer Risk in a Chinese Population. Asian Pacific Journal of Cancer Prevention, 2013, 14, 2433-2437.	1.2	25
40	Aspirin use and breast cancer risk: a meta-analysis. Breast Cancer Research and Treatment, 2012, 131, 581-587.	2.5	69
41	(-)-Epigallocatechin gallate sensitizes breast cancer cells to paclitaxel in a murine model of breast carcinoma. Breast Cancer Research, 2010, 12, R8.	5.0	110